Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The Bank of England meets eight times a year to set the base rate, which is the core interest ...